In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Proteins in wound healing
Do special amino acids lead to success?
- Psychedelic-assisted therapy
Current status of PAT
- Hepatitis B prophylaxis
Vaccination protection for healthcare staff with patient contact – an update
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Adrenogenital syndrome
Clinical care from birth to adulthood
- New approvals, current study data and ADC development
Antibody-drug conjugates in gynecologic oncology
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- From symptom to diagnosis